Strand Therapeutics picks up $52m Series A

Strand Therapeutics, a developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, has raised $52 million in Series A financing.

Strand Therapeutics, a developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, has raised $52 million in Series A financing. The investors included Redmile Group, BeiGene, Ltd., and Camford Capital.

Source: Press Release